vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and Hippo Holdings Inc. (HIPO). Click either name above to swap in a different company.
Hippo Holdings Inc. is the larger business by last-quarter revenue ($120.4M vs $83.5M, roughly 1.4× BillionToOne, Inc.). BillionToOne, Inc. runs the higher net margin — 6.8% vs 5.0%, a 1.9% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs 18.2%). Hippo Holdings Inc. produced more free cash flow last quarter ($9.1M vs $6.5M).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Hippo Valley Estate is a sugar estate found near the town of Chiredzi in Chiredzi District of southeastern Zimbabwe, on the Runde River near the border with Mozambique.
BLLN vs HIPO — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $120.4M |
| Net Profit | $5.7M | $6.0M |
| Gross Margin | 69.9% | — |
| Operating Margin | 11.5% | 5.6% |
| Net Margin | 6.8% | 5.0% |
| Revenue YoY | 117.4% | 18.2% |
| Net Profit YoY | 138.3% | -86.4% |
| EPS (diluted) | $0.10 | $0.31 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $120.4M | ||
| Q3 25 | $83.5M | $120.6M | ||
| Q2 25 | — | $117.3M | ||
| Q1 25 | — | $110.3M | ||
| Q4 24 | — | $101.9M | ||
| Q3 24 | $38.4M | $95.5M | ||
| Q2 24 | — | $89.6M | ||
| Q1 24 | — | $85.1M |
| Q4 25 | — | $6.0M | ||
| Q3 25 | $5.7M | $98.1M | ||
| Q2 25 | — | $1.3M | ||
| Q1 25 | — | $-47.7M | ||
| Q4 24 | — | $44.2M | ||
| Q3 24 | $-14.9M | $-8.5M | ||
| Q2 24 | — | $-40.5M | ||
| Q1 24 | — | $-35.7M |
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 5.6% | ||
| Q3 25 | 11.5% | 81.3% | ||
| Q2 25 | — | 3.4% | ||
| Q1 25 | — | -41.3% | ||
| Q4 24 | — | 46.3% | ||
| Q3 24 | -32.9% | -5.4% | ||
| Q2 24 | — | -40.7% | ||
| Q1 24 | — | -38.7% |
| Q4 25 | — | 5.0% | ||
| Q3 25 | 6.8% | 81.3% | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | -43.2% | ||
| Q4 24 | — | 43.4% | ||
| Q3 24 | -38.8% | -8.9% | ||
| Q2 24 | — | -45.2% | ||
| Q1 24 | — | -42.0% |
| Q4 25 | — | $0.31 | ||
| Q3 25 | $0.10 | $3.77 | ||
| Q2 25 | — | $0.05 | ||
| Q1 25 | — | $-1.91 | ||
| Q4 24 | — | $1.81 | ||
| Q3 24 | $-1.47 | $-0.34 | ||
| Q2 24 | — | $-1.64 | ||
| Q1 24 | — | $-1.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $218.3M |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $-239.5M | $436.1M |
| Total Assets | $327.5M | $1.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $218.3M | ||
| Q3 25 | $195.2M | $247.7M | ||
| Q2 25 | — | $198.9M | ||
| Q1 25 | — | $140.9M | ||
| Q4 24 | — | $197.6M | ||
| Q3 24 | — | $191.2M | ||
| Q2 24 | — | $175.9M | ||
| Q1 24 | — | $223.4M |
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $436.1M | ||
| Q3 25 | $-239.5M | $421.5M | ||
| Q2 25 | — | $332.5M | ||
| Q1 25 | — | $322.8M | ||
| Q4 24 | — | $362.1M | ||
| Q3 24 | $-242.9M | $326.4M | ||
| Q2 24 | — | $322.6M | ||
| Q1 24 | — | $351.2M |
| Q4 25 | — | $1.9B | ||
| Q3 25 | $327.5M | $1.9B | ||
| Q2 25 | — | $1.7B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $9.2M |
| Free Cash FlowOCF − Capex | $6.5M | $9.1M |
| FCF MarginFCF / Revenue | 7.7% | 7.6% |
| Capex IntensityCapex / Revenue | 8.8% | 0.1% |
| Cash ConversionOCF / Net Profit | 2.42× | 1.53× |
| TTM Free Cash FlowTrailing 4 quarters | — | $14.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $9.2M | ||
| Q3 25 | $13.8M | $16.9M | ||
| Q2 25 | — | $24.7M | ||
| Q1 25 | — | $-35.6M | ||
| Q4 24 | — | $47.5M | ||
| Q3 24 | — | $46.8M | ||
| Q2 24 | — | $-10.6M | ||
| Q1 24 | — | $17.7M |
| Q4 25 | — | $9.1M | ||
| Q3 25 | $6.5M | $16.8M | ||
| Q2 25 | — | $24.6M | ||
| Q1 25 | — | $-35.7M | ||
| Q4 24 | — | $47.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-10.7M | ||
| Q1 24 | — | $17.6M |
| Q4 25 | — | 7.6% | ||
| Q3 25 | 7.7% | 13.9% | ||
| Q2 25 | — | 21.0% | ||
| Q1 25 | — | -32.4% | ||
| Q4 24 | — | 46.3% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -11.9% | ||
| Q1 24 | — | 20.7% |
| Q4 25 | — | 0.1% | ||
| Q3 25 | 8.8% | 0.1% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | 1.53× | ||
| Q3 25 | 2.42× | 0.17× | ||
| Q2 25 | — | 19.00× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
HIPO
Segment breakdown not available.
